Next-Generation Sequencing: An Emerging Tool for Drug Designing

Pooja Tripathi, Jyotsna Singh, Jonathan A. Lal, Vijay Tripathi*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review


Background: With the outbreak of high throughput next-generation sequencing (NGS), the biological research of drug discovery has been directed towards the oncology and infectious disease therapeutic areas, with extensive use in biopharmaceutical development and vaccine production.

Method: In this review, an effort was made to address the basic background or NGS technologies, potential applications of NGS in drug designing. Our purpose is also to provide a brief introduction of various Next-generation sequencing techniques.

Discussions: The high-throughput methods execute Large-scale Unbiased Sequencing (LUS) which comprises of Massively Parallel Sequencing (MPS) or NGS technologies. The Next gene involved necessarily executes Large-scale Unbiased Sequencing (LUS) which comprises of MPS or NGS technologies. These are related terms that describe a DNA sequencing technology which has revolutionized genomic research. Using NGS, an entire human genome can be sequenced within a single day.

Conclusion: Analysis of NGS data unravels important clues in the quest for the treatment of various life threatening diseases and other related scientific problems related to human welfare.

Original languageEnglish
Pages (from-to)3350-3357
Number of pages8
JournalCurrent Pharmaceutical Design
Issue number31
Publication statusPublished - 2019


  • Next generation sequencing
  • drug discovery
  • high throughput sequencing
  • infectious disease
  • human welfare
  • Large-scale Unbiased Sequencing (LUS)
  • DNA

Cite this